Anika Therapeutics, Inc.

NasdaqGS:ANIK Stock Report

Market Cap: US$198.9m

Anika Therapeutics Management

Management criteria checks 4/4

Anika Therapeutics' CEO is Steve Griffin, appointed in Jun 2024, has a tenure of less than a year. total yearly compensation is $2.03M, comprised of 24.6% salary and 75.4% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $687.08K. The average tenure of the management team and the board of directors is 4.3 years and 4.7 years respectively.

Key information

Steve Griffin

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage24.59%
CEO tenure2yrs
CEO ownership0.3%
Management average tenure4.3yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 30

Bullish On Anika Therapeutics's Pullback As Integrity Scales

Summary Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK’s Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks. ANIK’s valuation seems quite cheap overall, with no financial debt and positive TTM cash flows. So, despite its inherent regulatory and execution risks, I remain bullish. Read the full article on Seeking Alpha
Analysis Article • Aug 06

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive

NasdaqGS:ANIK 1 Year Share Price vs Fair Value Explore Anika Therapeutics's Fair Values from the Community and select...
Analysis Article • May 10

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price

Anika Therapeutics, Inc.'s ( NASDAQ:ANIK ) price-to-sales (or "P/S") ratio of 1.4x might make it look like a strong buy...
Analysis Article • Dec 19

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 1.4x Anika Therapeutics, Inc. ( NASDAQ:ANIK ) may be sending very bullish...
Analysis Article • Jan 30

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Key Insights Anika Therapeutics' estimated fair value is US$44.70 based on 2 Stage Free Cash Flow to Equity Anika...
Analysis Article • Aug 03

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 11

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Anika Therapeutics' share price is being punished by the market owing to some possibly over-ambitious growth projections made in June last year. Management believed it could nearly double revenues, to $230m, by 2024, but after a so-so 2021, these plans have been abandoned. Anika is attempting to pivot from pain management and its Monovisc and Orthovisc injectables, to joint preservation, having acquired two businesses in 2020. Progress has not been bad - Anika is growing revenues, is profitable, and has nearly $100m cash - but it hasn't been as good as promised. I'm not entirely sure about Anika's long-term prospects, since it's moving away from its core revenues generating business into a new field, but I do think the market undervalues the business at current market cap of ~$350m.
Analysis Article • Jun 25

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Today we will run through one way of estimating the intrinsic value of Anika Therapeutics, Inc. ( NASDAQ:ANIK ) by...
Analysis Article • Mar 16

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

CEO Compensation Analysis

How has Steve Griffin's remuneration changed compared to Anika Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$2mUS$500k

-US$10m

Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$13m

Mar 31 2025n/an/a

-US$11m

Dec 31 2024US$3mUS$279k

-US$9m

Compensation vs Market: Steve's total compensation ($USD2.03M) is about average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Griffin (40 yo)

2yrs
Tenure
US$2,033,370
Compensation

Mr. Stephen D. Griffin, also known as Steve, is President, Chief Executive Officer and Director of Anika Therapeutics, Inc. since February 01, 2026 and serves as its Principal Financial Officer. He was Exe...

Leadership Team

NamePositionTenureCompensationOwnership
Cheryl Blanchard
Executive Chair7.8yrsUS$4.89m2.03%
$ 4.0m
Stephen Griffin
President2yrsUS$2.03m0.35%
$ 687.1k
Ian McLeod
Senior VP4.9yrsUS$765.54k0.18%
$ 360.3k
Matthew Hall
Executive Director of Corporate Development & Investor Relationsno datano datano data
James Chase
Senior VP of International Sales & Marketing6.1yrsno datano data
Ben Joseph
VP of Commercial & Corporate Development4.4yrsno datano data
Lisa Funiciello
VP & Chief Human Resources Officer4.3yrsno datano data
Mira Leiwant
Senior Vice President of Regulatory1.3yrsno datano data
4.3yrs
Average Tenure
60yo
Average Age

Experienced Management: ANIK's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cheryl Blanchard
Executive Chair7.8yrsUS$4.89m2.03%
$ 4.0m
Stephen Griffin
Presidentless than a yearUS$2.03m0.35%
$ 687.1k
William Jellison
Independent Director2.1yrsUS$225.00k0.067%
$ 133.6k
John Henneman
Lead Independent Director6.8yrsUS$267.50k0.41%
$ 820.0k
Sheryl Conley
Independent Director4.7yrsUS$225.00k0.21%
$ 424.5k
Glenn Larsen
Independent Director11.3yrsUS$212.50k0.27%
$ 539.4k
Joseph Capper
Independent Director2.1yrsUS$222.50k0.047%
$ 93.2k
Gary Fischetti
Independent Director3.2yrsUS$212.50k0.21%
$ 410.2k
Stephen Richard
Independent Director5.8yrsUS$230.00k0.25%
$ 503.8k
4.7yrs
Average Tenure
64yo
Average Age

Experienced Board: ANIK's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 08:57
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anika Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Anderson SchockB. Riley Securities, Inc.
Mark LandyNorthland Capital Markets